| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Schisantherin B targets multiple pathways involved in oxidative stress, inflammation, and metabolic regulation. It inhibits the formation of advanced glycation end products (AGEs), which are implicated in diabetic complications and aging. The compound also exhibits antioxidant activity by scavenging reactive oxygen species and enhancing cellular antioxidant defenses. Schisantherin B modulates inflammatory pathways, reducing the production of pro-inflammatory cytokines. Its hepatoprotective effects are mediated through the inhibition of oxidative stress and inflammation in the liver.
|
|---|---|
| ln Vitro |
In vitro, schisantherin B inhibits the formation of advanced glycation end products (AGEs), which are formed through non-enzymatic glycation of proteins. This activity suggests potential benefits in preventing diabetic complications and age-related diseases. The compound also exhibits antioxidant and anti-inflammatory activities, reducing oxidative stress and inflammation in various cell types. These in vitro studies confirm the diverse biological activities of schisantherin B.
|
| ln Vivo |
In vivo, schisantherin B has demonstrated hepatoprotective, antioxidant, anti-inflammatory, and neuroprotective effects in animal models. It has been used in traditional East Asian medicine to treat deficiency-syndrome. The compound's ability to inhibit AGE formation and reduce oxidative stress suggests potential benefits in preventing diabetic complications and other age-related diseases. Further in vivo studies would be required to fully characterize its therapeutic potential.
|
| Enzyme Assay |
In vitro enzyme/receptor binding (non-cellular) assays for schisantherin B are not extensively documented. However, the compound's ability to inhibit AGE formation can be assessed using cell-free assays. In these assays, schisantherin B is incubated with a protein (e.g., bovine serum albumin) and a reducing sugar (e.g., glucose) to induce glycation, and the formation of AGEs is measured using fluorescence spectroscopy. The compound's antioxidant activity can be assessed using standard assays such as DPPH radical scavenging or ABTS assays.
|
| Cell Assay |
In vitro cellular assays for schisantherin B are performed using various cell types, including hepatocytes, neurons, and immune cells. Cells are treated with schisantherin B and exposed to oxidative stress or inflammatory stimuli. The production of reactive oxygen species is measured using fluorescent dyes. Inflammatory cytokine expression is assessed by ELISA or quantitative PCR. Cell viability is evaluated using MTT assays. These assays confirm the antioxidant, anti-inflammatory, and cytoprotective activities of schisantherin B.
|
| Animal Protocol |
In vivo animal experiments for schisantherin B are conducted in models of liver injury, neuroinflammation, or diabetes. Mice or rats are administered schisantherin B via oral or intraperitoneal injection, and disease progression is monitored. Endpoints include serum markers of liver function, oxidative stress markers, inflammatory cytokine levels, and histopathological assessment of tissue damage. The compound's ability to inhibit AGE formation and reduce diabetic complications may also be evaluated in diabetic animal models.
|
| ADME/Pharmacokinetics |
Schisantherin B has a molecular weight of 514.56 g/mol and a molecular formula of C28H34O9. Detailed pharmacokinetic properties such as bioavailability, half-life, and tissue distribution have not been extensively reported in the available literature. As a lignan, schisantherin B may have moderate oral bioavailability and may undergo extensive metabolism. Further pharmacokinetic studies would be necessary to support its development as a therapeutic agent.
|
| Toxicity/Toxicokinetics |
Schisantherin B has been evaluated in preclinical studies and has been reported to be well-tolerated at effective doses. No significant toxicity has been reported in the available literature. However, comprehensive toxicology studies would be necessary to fully assess the compound's safety profile for clinical development. As a natural product with a long history of use in traditional medicine, schisantherin B is generally considered to have a favorable safety profile.
|
| References | |
| Additional Infomation |
Gomisin B is a tannin. It has been reported to be found in Schisandra chinensis, Schisandra chinensis, and other organisms with relevant data. See also: Schisandra chinensis fruit (partial).
Schisantherin B is a dibenzocyclooctadiene lignan isolated from *Schisandra chinensis* and *Schisandra sphenanthera* fruits. It exhibits hepatoprotective, antioxidant, anti-inflammatory, and neuroprotective effects. Schisantherin B inhibits the formation of advanced glycation end products (AGEs) in vitro. It is used in traditional East Asian medicine to treat deficiency-syndrome. Schisantherin B is a research compound with potential applications in metabolic and age-related diseases. |
| Molecular Formula |
C28H34O9
|
|---|---|
| Molecular Weight |
514.57
|
| Exact Mass |
514.22
|
| CAS # |
58546-55-7
|
| PubChem CID |
6438572
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
675.0±55.0 °C at 760 mmHg
|
| Flash Point |
220.3±25.0 °C
|
| Vapour Pressure |
0.0±2.2 mmHg at 25°C
|
| Index of Refraction |
1.586
|
| LogP |
3.84
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
37
|
| Complexity |
833
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C/C=C(/C)\C(=O)O[C@H]1C2=CC(=C(C(=C2C3=C(C4=C(C=C3C[C@@H]([C@]1(C)O)C)OCO4)OC)OC)OC)OC
|
| InChi Key |
BKGUPIVDQHHVMV-RZGKOBFOSA-N
|
| InChi Code |
InChI=1S/C28H34O9/c1-9-14(2)27(29)37-26-17-12-18(31-5)22(32-6)25(34-8)21(17)20-16(10-15(3)28(26,4)30)11-19-23(24(20)33-7)36-13-35-19/h9,11-12,15,26,30H,10,13H2,1-8H3/b14-9-/t15-,26-,28-/m0/s1
|
| Chemical Name |
[(8S,9S,10S)-9-hydroxy-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.02,7.014,18]nonadeca-1(19),2,4,6,12,14(18)-hexaen-8-yl] (Z)-2-methylbut-2-enoate
|
| Synonyms |
Schisandrer B; Gomisin B; Schisantherin B
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~97.17 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.86 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.86 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9434 mL | 9.7169 mL | 19.4337 mL | |
| 5 mM | 0.3887 mL | 1.9434 mL | 3.8867 mL | |
| 10 mM | 0.1943 mL | 0.9717 mL | 1.9434 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
